Details for Patent: 10,570,142

Which drugs does patent 10,570,142 protect, and when does it expire?

Patent 10,570,142 protects UKONIQ and is included in one NDA.

This patent has fifty-three patent family members in thirty countries.

Drugs Protected by US Patent 10,570,142

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Tg Theraps	UKONIQ	umbralisib tosylate	TABLET;ORAL	213176-001	Feb 5, 2021		DISCN	Yes	No			Y	Y		RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY
Tg Theraps	UKONIQ	umbralisib tosylate	TABLET;ORAL	213176-001	Feb 5, 2021		DISCN	Yes	No			Y	Y		RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN

International Family Members for US Patent 10,570,142

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	091677
Australia	2013285081
Brazil	112014033055
Canada	2876995